BICX — BioCorRx Inc.
—
OTC ·
Health Care ·
Health Care Providers & Services ·
CIK 1443863 ·
Last close
$0.40
Market Cap
$11.62M
52W High
$1.28
52W Low
$0.24
ADV30
2,120
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 214,539 | 189,355 | -587,029 | -831,227 | 2,324,865 | 211,911 | 13,948,134 |
| Dec 2025 | -151,118 | 185,893 | 466,284 | 552,555 | 2,147,212 | 139,360 | 13,674,200 |
| Sep 2025 | 635,224 | 276,412 | -1,078,457 | -1,917,873 | 7,533,473 | 287,688 | 20,297,768 |
| Jun 2025 | 178,238 | 178,238 | -1,259,650 | -1,233,418 | 6,680,879 | 111,872 | 19,694,108 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,298,291
Investing CF
—
Financing CF
$2,349,618
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-86,649,288
Inventory
$143,425
Receivables
$305,485
ST Investments
—
EBIT TTM
$-2,647,204
Pretax Income TTM
$-3,508,760
Interest Exp TTM
$861,556
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$876,884
EBITDA
$-4,812,967
Free Cash Flow
$-7,021,148
Enterprise Value
$13,414,982
Total Cash
$211,911
Total Debt
$2,156,317
Shares Out
29,055,547
Trailing EPS
$-0.16
Book Value
$-0.40
ROE
—
ROA
-66.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 797,244 | -2,395,794 | -3,440,146 | 2,147,212 | 13,674,200 | — | -2,298,291 |
| Dec 2024 | 7,665 | -3,649,229 | -5,106,124 | 385,941 | 12,741,173 | — | -1,096,254 |
| Dec 2023 | 89,160 | -2,806,820 | -3,766,913 | 388,887 | 10,341,411 | — | -1,853,282 |
| Dec 2022 | 213,841 | -2,908,499 | -4,369,413 | 766,594 | 8,968,325 | — | -2,041,773 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$659
NetIncome TTM
$-6,752
OpCashFlow TTM
$0
Assets (Latest)
$4,061,511
Forward EPS
$-0.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PFHO | PACIFIC HEALTH CARE ORGANIZATION INC | $12.03M | $0.94 | — |
| BMGL | Basel Medical Group Ltd | $10.89M | $0.58 | — |
| MRAI | Marpai, Inc. | $10.88M | $0.43 | — |
| CCM | Concord Medical Services Holdings Ltd | $13.77M | $4.89 | — |
| MGRX | MANGOCEUTICALS, INC. | $9.41M | $0.55 | — |
News headlines (Yahoo Finance, 1h cache)
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
2026-03-11 12:30 · Yahoo
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
2026-01-14 13:30 · Yahoo
BioCorRx Announces Appointment of Louis Lucido as Board Chair
2026-01-06 13:30 · Yahoo
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
2025-12-24 13:30 · Yahoo
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
2025-12-10 13:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
2025-12-09 13:35 · Yahoo
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
2025-11-18 13:30 · Yahoo
Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)
2025-08-25 12:00 · Yahoo
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
2025-08-14 18:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.